Gilead Sciences

Health Care Biotechnology Foster City, California Last filing Feb 24, 2026 · FY2025

                    Revenue
                    FY2025
                
$29.4B
                    3y CAGR +2.6%
                    
                    P34
                    
                    n/a
                    
                    Net income
                    FY2025
                
$8.5B
                    Net margin +28.9%
                    
                    P95
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$59.0B
                    ROA +14.4%
                    
                    P88
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$10.0B
                    FCF margin +32.1%
                    
                    P98
                    
                    n/a

19 yrs · FY2007–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s total assets.

Balance Sheet

Assets, liabilities, and equity

29 accounts · 1 year

Total assets $59.0B

Total liabilities $11.8B

Shareholders equity $22.7B

Account	2025	Trend
Assets
Cash and Cash Equivalents	12.8%
Short Term Investments	0.0%
Accounts Receivable	8.3%
Inventory	3.0%
Prepaid Expenses	6.8%
Total Current Assets	31.1%
Property,Plant and Equipment	9.5%
Goodwill	14.1%
Intangible Assets	28.8%
Deferred Tax Assets	3.3%
Other Noncurrent Assets	8.2%
Total Assets	100.0%
Liabilities
Accounts Payable	1.2%
Accrued Liabilities	0.0%
Current Portion of Long Term Debt	4.8%
Other Current Liabilities	6.7%
Total Current Liabilities	20.0%
Long Term Debt	37.5%
Deferred Tax Liabilities	0.7%
Other Noncurrent Liabilities	2.0%
Total Liabilities	20.0%
Equity
Preferred Stock	0.0%
Common Stock	0.0%
Additional Paid In Capital	15.1%
Retained Earnings	23.3%
Accumulated Other Comprehensive Income	0.1%
Noncontrolling Interest	-0.1%
Total Stockholders Equity	38.5%
Total Liabilitiesand Equity	100.0%

Income Statement

Revenue, expense, and profitability

20 accounts · 1 year

Revenue $29.4B

Operating income $10.0B

Net income $8.5B

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	49.9%
Expenses Cost of Revenue	10.6%
Expenses Research and Development	9.8%
Expenses Selling,General and Administrative	9.8%
Expenses Depreciation and Amortization	4.1%
Expenses Share Based Compensation	1.5%
Expenses Restructuring and Asset Impairment	0.2%
Expenses Operating Expenses	32.9%
Other Income Expense Operating Income	17.0%
Other Income Expense Interest Income	0.6%
Other Income Expense Interest Expense	1.7%
Other Income Expense Other Income/expense	-0.0%
Other Income Expense Income Before Tax	16.6%
Income Tax Income Tax Expense	2.2%
net Income net Income	14.4%
net Income Comprehensive Income	14.3%
Earnings Per Share Basic Eps	0.0%
Earnings Per Share Diluted Eps	0.0%
Earnings Per Share Weighted Average Shares Basic	2.1%
Earnings Per Share Weighted Average Shares Diluted	2.1%

Cash Flow Statement

Operating, investing, and financing flows

23 accounts · 1 year

Operating cash flow $10.0B

Investing cash flow $-4.8B

Financing cash flow $-7.7B

Account	2025	Trend
CashFlow
Operating Activities net Income	14.4%
Operating Activities Depreciation and Amortization	0.6%
Operating Activities Stock Based Compensation	1.5%
Operating Activities Deferred Income Taxes	0.3%
Operating Activities Changes In Operating Assets and Liabilities	2.7%
Operating Activities net Cash From Operating Activities	17.0%
Investing Activities Capital Expenditures	1.0%
Investing Activities Business Acquisitions	1.8%
Investing Activities Purchases of Investments	6.7%
Investing Activities Proceeds From Sale of Investments	0.1%
Investing Activities Other Investing Activities	-0.0%
Investing Activities net Cash From Investing Activities	-8.1%
Financing Activities Proceeds From Debt	0.0%
Financing Activities Repayment of Debt	3.0%
Financing Activities Repurchase of Common Stock	3.3%
Financing Activities Dividends Paid	6.8%
Financing Activities Proceeds From Stock Issuance	0.7%
Financing Activities Other Financing Activities	-0.7%
Financing Activities net Cash From Financing Activities	-13.1%
Cash Reconciliation Effect of Exchange Rate On Cash	0.2%
Cash Reconciliation net Change In Cash	-4.1%
Cash Reconciliation Cash At Beginning of Period	12.8%
Cash Reconciliation Cash At End of Period	12.8%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	+78.8%
Operating margin	+34.0%
Net margin	+28.9%
FCF margin	+32.1%
Growth
Revenue CAGR (3y)	+2.6%
Returns
ROE	+37.5%
ROA	+14.4%
ROIC	+21.7%
Liquidity
Current ratio	1.55x
Quick ratio	1.06x
Leverage
D/E	0.52x
Interest coverage	9.79x
Efficiency
Asset turnover	0.50x
Cash conversion cycle	+123d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Gilead Sciences

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history